Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Advances in Clinical Research on Mcl-1 Inhibitors
25 September 2023
Mcl-1, also known as myeloid cell leukemia-1, is a protein that plays a crucial role in regulating cell survival and apoptosis (programmed cell death) in the human body.
Drug Insights
3 min read
A Comprehensive Review of Lymecycline's R&D Innovations and Drug Target Mechanism
25 September 2023
This article summarized the latest R&D progress of Lymecycline, the Mechanism of Action for Lymecycline, and the drug target R&D trends for Lymecycline.
Latest Hotspot
3 min read
The first participant in ImmPACT Bio's Phase 1/2 study has received treatment with IMPT-314, aimed at combatting aggressive B-cell Lymphoma
25 September 2023
ImmPACT Bio USA, Inc has publicized that the initial patient has received treatment in the Phase 1/2 trial of IMPT-314.
Drug Insights
4 min read
Pharmaceutical Insights: Dydrogesterone's R&D Progress
25 September 2023
This article summarized the latest R&D progress of Dydrogesterone, the Mechanism of Action for Dydrogesterone, and the drug target R&D trends for Dydrogesterone.
Valuable Targets
6 min read
Progress of IL-17A Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases
25 September 2023
IL-17A, or Interleukin-17A, is a cytokine that plays a crucial role in the human body's immune response.
Drug Insights
4 min read
ExploringCeftolozane's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
22 September 2023
This article summarized the latest R&D progress of Ceftolozane, the Mechanism of Action for Ceftolozane, and the drug target R&D trends for Ceftolozane.
Latest Hotspot
3 min read
MRM Health showcases encouraging findings from its Phase 2a Clinical Trial of MH002 for Ulcerative Colitis
22 September 2023
MRM Health NV has announced encouraging preliminary outcomes from its Phase 2a clinical study of MH002 against mild-to-moderate Ulcerative Colitis.
Drug Insights
4 min read
Decoding Tetracaine: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
22 September 2023
This article summarized the latest R&D progress of Tetracaine, the Mechanism of Action for Tetracaine, and the drug target R&D trends for Tetracaine.
Valuable Targets
5 min read
Analysis on the Clinical Research Progress of IL-23 inhibitors
22 September 2023
IL-23, or Interleukin-23, is a crucial cytokine that plays a significant role in the human body's immune response.
Drug Insights
5 min read
Deep Scientific Insights on Tesofensine's R&D Progress, Mechanism of Action, and Drug Target
22 September 2023
This article summarized the latest R&D progress of Tesofensine, the Mechanism of Action for Tesofensine, and the drug target R&D trends for Tesofensine.
Latest Hotspot
3 min read
Patient Receives First Dose of ALPK1 Inhibitor, DF-003, in Drug Farm's Phase 1 Clinical Trial
22 September 2023
Drug Farm, currently in the clinical phase, has shared the news of the first participant in the Phase 1 clinical experiment, testing DF-003, receiving their initial dosage.
Drug Insights
4 min read
An In-depth Analysis of Tenecteplase's R&D Progress and Mechanism of Action on Drug Target
22 September 2023
This article summarized the latest R&D progress of Tenecteplase, the Mechanism of Action for Tenecteplase, and the drug target R&D trends for Tenecteplase.